Contact Us

Contact Us

Please contact us below with any questions

info@quadratech.co.uk

+44 (0)33 3321 2371

Side Contact
×
Sign up to our newsletter Click Here
quadratech Logo
{{ toggleHam ? 'CLOSE' : 'MENU' }}
Next Day & International Delivery
Competitive Pricing
Over 30 Years Experience
Based In The UK

Human IgG1 Anti SARS-CoV-2 Spike (S1) Antibody (CR3022) (100µg)

X

We're always working hard to give our customers as much information on products and the best price possible. If you need any assistance or would like a quote please contact us and we will be happy to help

Human IgG1 Anti SARS-CoV-2 Spike (S1) Antibody (CR3022) (100µg) (QTXAB-398-100) is Human IgG1 anti SARS-CoV-2 Spike (S1) antibody (CR3022) is a monoclonal antibody that recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein, the causative agent of COVID-19. Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein. Suitable for use as a capture or detection antibody in ELISa assays. Horseradish peroxidase (HRP) and Biotin conjugated antibody also available.

Product Brand:
Product Code: QTXAB-398-100
Description

Anti SARS-CoV-2 Spike (S1) antibody (CR3022) is a recombinant monoclonal antibody that recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein, the causative agent of COVID-19. Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at amino acids 318-510 (RBD, Receptor Binding Domain) in the S1 subunit of the Spike protein. Suitable for use as a capture or detection antibody in ELISA assays.

Product Specification
Specification Type
Specification Value
Product Range
Product Code
QTXAB-398-100
Product Name
Human IgG1 Anti SARS-CoV-2 Spike (S1) Antibody (CR3022) (100µg)
Product Category
Product Brand
Product Analyte or Application
Product Size
1 x 100 µg
Product Storage
Long Term: -20°C or below,Short Term: 2°C to 8°C

Our Accreditations

Cookie Consent

Cookies help us deliver our services. By using our services, you agree to our use of cookies.